Oruka Therapeutics, Inc.
ORKA
$41.13
-$0.63-1.50%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.41M | 20.62M | 19.26M | 17.74M | 12.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 122.05M | 125.08M | 120.42M | 113.48M | 95.26M |
| Operating Income | -122.05M | -125.08M | -120.42M | -113.48M | -95.26M |
| Income Before Tax | -105.43M | -109.24M | -107.59M | -105.26M | -84.26M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.43 | -109.24 | -107.59 | -105.26 | -84.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.43M | -109.24M | -107.59M | -105.26M | -91.34M |
| EBIT | -122.05M | -125.08M | -120.42M | -113.48M | -95.26M |
| EBITDA | -121.97M | -125.00M | -120.36M | -91.95M | -66.88M |
| EPS Basic | -1.85 | -1.94 | -2.86 | -9.35 | -24.13 |
| Normalized Basic EPS | -1.45 | -1.57 | -2.33 | -6.32 | -6.00 |
| EPS Diluted | -1.85 | -1.94 | -2.86 | -9.35 | -24.13 |
| Normalized Diluted EPS | -1.45 | -1.57 | -2.33 | -6.32 | -6.00 |
| Average Basic Shares Outstanding | 182.43M | 171.70M | 142.65M | 103.75M | 62.07M |
| Average Diluted Shares Outstanding | 182.43M | 171.70M | 142.65M | 103.75M | 62.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |